A Phase 4 interventional study of sildenafil and placebo in Spinal Cord Injury, Erectile Dysfunction and Spinal Cord Trauma, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 5 sites in Turkey. Open to male participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2021-02-01.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Spinal Cord Injuries with a site in Turkey — 16 open to participants now, 18 under way, 1 of them phase 3. Spinal Cord Injuries · Turkey.
Among the 62 studies in Spinal Cord Injuries with a site in Turkey, this one is the 2nd largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2002, is the only one in phase 4, and was the 1st registered.
2,028 studies on the registry are indexed under Spinal Cord Injuries; 540 are open to participants now.
Browse Spinal Cord Injuries studies →16 of the 62 studies in Spinal Cord Injuries with a site in Turkey are open now. Recruiting first, the newest first:
Gaziler Physical Medicine and Rehabilitation Education and Research Hospital · Sites in Turkey
Ages 18+
Istanbul Physical Medicine Rehabilitation Training and Research Hospital · Sites in Turkey
Ages 18–65
Nuh Naci Yazgan University · Sites in Turkey
Ages 18–55
Istanbul Medeniyet University · Sites in Turkey
Ages 16+
Ankara Etlik City Hospital · Sites in Turkey
Ages 18–65
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 376 Spinal Cord Injuries studies recruiting now, 167 (44%) set no upper age limit and 158 (42%) stop at 75 or younger; 41 take children under 18; 52 take healthy volunteers.
This study: 19 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 88 is above the median of 24 across 1,635 interventional studies indexed under Spinal Cord Injuries.
Median enrollment 34 across the 31 interventional studies, 50 across the 31 observational. Of the 43 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 62 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 4 studies filed under Spinal Cord Injuries — fewer than ten, so there is no comparison to draw.
4 of the studies in Spinal Cord Injuries with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07846410Istanbul Physical Medicine Rehabilitation Training and Research HospitalVirtual Reality-Based Hypnotherapy for Pain, Sleep, and Mood in Spinal Cord Injury | 2026-11 |
| NCT07849062Nuh Naci Yazgan UniversityRobot-Assisted Intensive Physiotherapy in Individuals With Spinal Cord Injury | 2027-02 |
| NCT07865338Gaziler Physical Medicine and Rehabilitation Education and Research HospitalPatterns of Rehabilitation After Spinal Cord Injury | 2027-03-30 |
| NCT07293780Ankara Etlik City HospitalEffect of TMS on Neuropathic Pain for Patients With Spinal Cord Injury | 2027-05-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 62 studies in Spinal Cord Injuries with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To demonstrate the efficacy, safety and tolerability of sildenafil administered orally, as required, approximately 1 hour prior to sexual activity to men with erectile dysfunction (ED) associated with spinal cord injury (SCI), as well as its effects on the quality of life (QoL) of these patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-Patients were men with spinal cord injury and erectile dysfunction
Exclusion Criteria:
-N/A
Drug: sildenafil
Drug: placebo
sildenafil 50 mg tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks; after 2 weeks on treatment, doses could be escalated to 100 mg or reduced to 25 mg
placebo tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks
The proportion of subjects who indicated a preference for either treatment and who said that the treatment improved their erections
Time frame: Weeks 6 and 14
Responses to the International Index of Erectile Function (IIEF)
Time frame: Weeks 0, 6, 8, and 14
Responses to the Global Efficacy Assessment (GEA) Question
Time frame: Weeks 0, 6, 8, and 14
Responses to questions on the Quality of Life (QoL) Questionnaire
Time frame: Weeks 0, 6, 8, and 14
Responses to Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questions
Time frame: Weeks 0, 6, 8, and 14
Intercourse success rate derived from patient event log
Time frame: Weeks 0, 6, 8, and 14
The record gives a start of Sep 2002 and a completion of Aug 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sildenafil
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →